Texas' top court nixes $32M Vioxx award

Merck ($MRK) won a reversal of the $32 million jury verdict in a Texas case over the Vioxx painkiller. The state's Supreme Court decided that the family of Leonel Garza didn't produce enough evidence to show Vioxx caused his heart attack, thus tossing out the 2006 verdict. Report

Suggested Articles

Roche
Pharma

Roche's Actemra helps keep COVID patients off ventilators

In a trial called Empacta, Roche's IL-6 inhibitor cut ventilator use, but didn't significantly cut the risk of death in COVID-19 pneumonia patients.

by Angus Liu
New York City
Pharma

J&J faces insurance fraud charges in N.Y. over opioid marketing

Officials in New York charged Johnson & Johnson with violating insurance laws with its opioid marketing.

by Eric Sagonowsky
Dermatology
Pharma

ESMO: Libtayo scores 31% response in basal cell carcinoma

Regeneron and Sanofi hope their PD-1 inhibitor Libtayo will be the first immuno-oncology treatment approved to treat basal cell carcinoma.

by Arlene Weintraub